Second- and third-line treatment of metastatic breast cancer with gemcitabine

被引：9
|
作者：
Brodowicz, T
Möslinger, R
Herscovici, V
Vaclavik, I
Wiltschke, C
Kubista, E
Zielinski, C
机构：
[1] Univ Vienna, Clin Div Oncol, A-1010 Vienna, Austria
[2] Univ Vienna, Chair Med Expt Oncol, A-1010 Vienna, Austria
[3] Univ Vienna, Dept Obstet & Gynaecol, A-1010 Vienna, Austria
[4] Univ Vienna, Dept Internal Med 1, A-1010 Vienna, Austria
来源：
EUROPEAN JOURNAL OF CANCER | 1998年 / 34卷
关键词：
D O I：
10.1016/S0959-8049(98)80169-X
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
180
引用
收藏
页码：S44 / S44
页数：1
相关论文
共 50 条
  • [31] Amrubicin as second- or third-line treatment for women with metastatic HER2-negative breast cancer: a Sarah Cannon Research Institute phase 1/2 trial
    Denise A. Yardley
    Eric Raefsky
    John D. Hainsworth
    Howard A. Burris
    Victor Priego
    Alejandro Inclan
    Breast Cancer Research and Treatment, 2014, 148 : 535 - 540
  • [32] Causes of resistance and treatment choices of second- and third-line treatment in chronic myelogenous leukemia patients
    Andreas Hochhaus
    Thomas Ernst
    Ekkehard Eigendorff
    Paul La Rosée
    Annals of Hematology, 2015, 94 : 133 - 140
  • [33] Algorithm for identifying various second- and third-line chemotherapy regimens in elderly US Medicare patients with metastatic colon cancer
    Bikov, Kaloyan A.
    Mullins, C. Daniel
    Onukwugha, Ebere
    Seal, Brian S.
    Hanna, Nader
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [34] Second- and third-line treatment strategies in multiple myeloma: a referral-center experience
    Goldman-Mazur, Sarah
    Visram, Alissa
    Rajkumar, S. Vincent
    Kapoor, Prashant
    Dispenzieri, Angela
    Lacy, Martha Q. Q.
    Gertz, Morie A. A.
    Buadi, Francis K. K.
    Hayman, Suzanne R. R.
    Dingli, David
    Kourelis, Taxiarchis
    Gonsalves, Wilson
    Warsame, Rahma
    Muchtar, Eli
    Leung, Nelson
    Kyle, Robert A. A.
    Kumar, Shaji K. K.
    BLOOD CANCER JOURNAL, 2022, 12 (12)
  • [35] Successful Remission of Hemolytic-Uremic Syndrome During the Third-line Weekly Gemcitabine for Metastatic Breast Cancer
    Kok, Victor C.
    Wu, Sheng-Chung
    Lee, Chien-Kuang
    BREAST CANCER-BASIC AND CLINICAL RESEARCH, 2014, 8 : 57 - 59
  • [36] Cost-effectiveness of tisotumab vedotin as a second- or third-line therapy for cervical cancer
    Huo, Gengwei
    Liu, Wenjie
    Chen, Peng
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2024, 35 (05)
  • [37] Delphi consensus for the third-line treatment of metastatic colorectal cancer
    Garcia-Alfonso, Pilar
    Vera, Ruth
    Aranda, Enrique
    Elez, Elena
    Rivera, Fernando
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2024, 26 (06): : 1429 - 1437
  • [38] Sequencing Considerations in the Third-Line Treatment of Metastatic Colorectal Cancer
    Barzi, Afsaneh
    Bekaii-Saab, Tanios
    AMERICAN JOURNAL OF MANAGED CARE, 2024, 30 (02): : S31 - S35
  • [39] A pilot study of nimotuzumab plus single agent chemotherapy as second- or third-line treatment or more in patients with recurrent, persistent or metastatic cervical cancer
    Cetina, Lucely
    Crombet, Tania
    Jimenez-Lima, Roberto
    Zapata, Sergio
    Ramos, Mayra
    Avila, Sandra
    Coronel, Jaime
    Charco, Eduardo
    Bojalil, Rafael
    Astudillo, Horacio
    Bazan, Blanca
    Duenas-Gonzalez, Alfonso
    CANCER BIOLOGY & THERAPY, 2015, 16 (05) : 684 - 689
  • [40] Second- and third-line treatment strategies in multiple myeloma: a referral-center experience
    Sarah Goldman-Mazur
    Alissa Visram
    S. Vincent Rajkumar
    Prashant Kapoor
    Angela Dispenzieri
    Martha Q. Lacy
    Morie A. Gertz
    Francis K. Buadi
    Suzanne R. Hayman
    David Dingli
    Taxiarchis Kourelis
    Wilson Gonsalves
    Rahma Warsame
    Eli Muchtar
    Nelson Leung
    Robert A. Kyle
    Shaji K. Kumar
    Blood Cancer Journal, 12
12345